Peer-reviewed veterinary case report
Imepitoin drug levels and use for treating epilepsy in dogs
By Rundfeldt, C et al.·Published in Journal of veterinary pharmacology and therapeutics·2014·Drug-Consult.Net, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Imepitoin as novel treatment option for canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism in dogs.
- Species:
- dog
Plain-English summary
A group of beagle dogs with idiopathic epilepsy (a type of seizure disorder with no known cause) were given a new medication called imepitoin to see how well it worked. The dogs showed high levels of the drug in their blood within 30 minutes of taking it, and it reached its peak effectiveness in about 2-3 hours. The study found that giving the medication with food slightly reduced its overall absorption, but this didn't seem to affect how well it worked. Overall, imepitoin appears to be a promising treatment option for managing seizures in dogs, and it can be given twice daily as long as it's taken at the same time relative to meals.
People also search for: dog seizure treatment · imepitoin for dogs · beagle epilepsy medication
Abstract
Imepitoin is a novel anti-epileptic licensed in the European Union for the treatment of canine idiopathic epilepsy. The aim of this study was to characterize the pharmacokinetics of imepitoin in dogs and to evaluate the interaction with drug metabolizing enzymes. Upon administration of imepitoin tablets at a dose of 30 mg/kg to beagle dogs, high plasma levels were observed within 30 min following oral dosing, with maximal plasma concentrations of 14.9-17.2 μg/mL reached after 2-3 h. In a crossover study, co-administration of imepitoin tablets with food reduced the total AUC by 30%, but it did not result in significant changes in Tmax and Cmax , indicating lack of clinical relevance. No clinically relevant effects of sex and no accumulation or metabolic tolerance were observed upon twice daily dosing. Following single dose administration of 10-100 mg/kg, dose linearity was found. Administering [(14) C] imepitoin, high enteral absorption of 92% and primary fecal excretion were identified. Plasma protein binding was only 55%. At therapeutic plasma concentrations, imepitoin did not inhibit microsomal cytochrome P450 family liver enzymes in vitro. In rats, no relevant induction of liver enzymes was found. Therefore, protein binding or metabolism-derived drug-drug interactions are unlikely. Based on these data, imepitoin can be dosed twice daily, but the timing of tablet administration in relation to feeding should be kept consistent.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24611573/